cas 2711862-49-4|| where to buy 1,1-Dimethylethyl (2S)-2-[(2S)-4-bromo-5-chloro-6-fluoro-2,3-dihydro-2-phenyl-2-benzofuranyl]-1-pyrrolidinecarboxylate

製品名:1,1-Dimethylethyl (2S)-2-[(2S)-4-bromo-5-chloro-6-fluoro-2,3-dihydro-2-phenyl-2-benzofuranyl]-1-pyrrolidinecarboxylate

IUPAC Name:tert-butyl (2S)-2-[(2S)-4-bromo-5-chloro-6-fluoro-2-phenyl-2,3-dihydro-1-benzofuran-2-yl]pyrrolidine-1-carboxylate

包装単位	有効在庫	価格（USD）	数量

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2711862-49-4 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2711862-49-4; 分子式:C23H24BrClFNO3; 融点:-; SMILESコード:C(OC(C)(C)C)(=O)N1[C@]([C@]2(CC=3C(O2)=CC(F)=C(Cl)C3Br)C4=CC=CC=C4)(CCC1)[H]; 密度:1.439±0.06 g/cm3

: カタログ番号:CM1077690; 分子量:496.8; 沸点:528.9±50.0 °C; MDL番号:; 保管方法:

: Benzofurans; Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.; Benzofuran | C8H6O | CID 9223 -Chemenu; Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans; Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

: IAG933; IAG933 is a potent, selective, and first-in-class inhibitor from Novartis that directly inhibits the protein-protein interaction (PPI) between YAP/TAZ and TEAD. By blocking this PPI, IAG933 interferes with oncogenic functions downstream of the Hippo signaling pathway, particularly in mesothelioma and other tumors with NF2 loss-of-function mutations or YAP/TAZ fusions. This inhibition reduces transcriptional activity and induces cell death in cancer cells, leading to significant tumor regressions in xenograft models. Additionally, combining IAG933 preclinically with other targeted therapies (i.e., RTK, KRAS-mutant selective, and MAPK inhibitors) shows promise for improving the efficacy and durability of treatment responses. IAG933 is currently being evaluated in a Ph. I trial (NCT04857372) for solid tumors with Hippo pathway alterations.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.